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Background: Several quinazoline and triazole derivatives are reported to possess a wide-range of interesting
pharmacological effects. Although various triazoloquinazoline subclasses having been synthesized and studied,
the preparation of 1,2,4-triazolo[1,5-a]quinazolines as antihypertensive agent is still relatively unexplored. In
continuation of our earlier research, we aimed at the synthesis and development of various potent antihypertensive
1,2,4-triazoloquinazoline derivatives.
Results: A new series of 1,2,4-triazolo[1,5-a]quinazoline derivatives have been synthesized. Their structures were
mainly established by spectroscopic methods of analysis (IR, MS, 1H and 13C NMR). Their in vivo antihypertensive
activity was evaluated by tail cuff method using Muromachi Blood Pressure Monitor (Model MK 2000) for rats and
mice. Some of the tested compounds were found to exhibit valuable effects in terms of heart rate and blood
pressure. According to the biological results, some of tested derivatives have abolished completely the tachycardia
of the parent compounds and may be studied and modified as potential adrenoblockers and cardiac stimulant.
Conclusion: New series of fifteen 1,2,4-triazolo[1,5-a]quinazolines were synthesized by convenient methodology
from four key molecules, whereby their structures were established by advanced spectroscopic analyses. Some lead
compounds have abolished completely the tachycardia of the parent compounds, that may be examined as potent
adrenoblockers and some other compounds seem to be a cardiac stimulant or may be modified to enhance their
hypotensive activity.
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Arterial diseases cause more premature deaths than all
other disorders such as cancer and infections combined.
High blood pressure has been identified as the most
powerful one among the major risk factors for arterial
diseases [1]. Now-a-days, several efforts have been
made in search of potent anti-hypertensive drugs because
hypertension was commonly proved to cause heart failure.
Quinazolines and their condensed products are reported to
possess several interesting pharmacological effects
such as antihypertensive [2], antihistaminic [3,4], analgesic,
anti-inflammatory [5,6], anticancer [7], and anti-HIV [8]
activities. Prazocin, terazocin and doxazocin as quinazoline
derived α-1 blockers, are reputed class of antihypertensive* Correspondence: msmarzouk@yahoo.co.uk
1Department of Pharmacetical Chemistry, College of Pharmacy, King Saud
University, P. O. Box 2457, Riyadh 11451, Saudi Arabia
Full list of author information is available at the end of the article
© 2014 Al-Salahi et al.; licensee Chemistry Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.agents. In spite of various triazoloquinazoline systems
having been synthesized and studied, the elaborating of
1,2,4-triazolo[1,5-a]quinazoline as antihypertensive agent is
still relatively unexplored [1]. Moreover, Some of potent
antihypertensive 1,2,4-triazoloquinazoline derivatives were
reported [1]. In view of these facts and continuation to our
earlier reported triazoloquinazolines researches [1,9-12],
we aimed at synthesis of various substituted 1,2,4-triazolo
[1,5-a]quinazolines and evaluation their biological effects
on heart rate and blood pressure.
Results and discussion
Synthetic chemistry
As outlined in Scheme 1, the target molecules were
synthesized by starting with the preparation of our
key materials (1–4) according to the literature [13-15].
The structures of 1–3 were characterized by NMR, MS,
IR spectra and compound 1 has been unambiguouslytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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Scheme 1 Synthesis of [1,2,4]triazolo[1,5-a]quinazoline derivatives.
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N-alkylation has been well documented in the literature
[13,14]. Accordingly, when the triazoloquinazolin-5-ones
(1,4) were allowed to react with alkyl halides in a molar
ratio of 1:1.5 in dry dimethyl formamide at room
temperature in the presence of potassium carbonate, the
corresponding 4-alkyl[1,2,4]triazolo[1,5-a]quinazolin-5-
ones (5–10) resulted in 71-87% yield. The products 5–10
were obtained as coloress solid and their IR spectra
displayed a strong (C = O) absorption band in the
range of 1675–1689 cm−1. When equimolar amounts of
triazoloquinazolin-5-one 1 and phosphorus pentasulfide
were allowed to react in dry pyridine under reflux for 3 h,
the desired triazoloquinazolin-5-thione (15) could be
isolated as yellow solid in excellent yield of 92% [18].
The IR spectra of compound 15 displayed a weak (C = S)
absorption band at around 1197 cm−1 and characterized
by NMR and MS spectra. The structure of compound
16 has been previously proved by NMR, MS and X-ray
[14,17]. Treatment of the [1,2,4]triazoloquinazolin-5-thione
15 with different alkyl halides in aqueous sodium hydroxide
solution (2 M) afforded smoothly the expected thioethers
(17–19) in 54-75% yield. Conversion of [1,2,4]triazoloquina-
zolin-5-ones (1,2,4) into 5-chloro-[1,2,4]triazolo[1,5-a]
quinazolines (11–13) have been successfully achieved
by phosphorus oxychloride in boiling benzene for 2.5 h,
followed by treatment with a saturated aqueous solution
of potassium carbonate [19]. The formation of 11–13was accompanied by the gradual disappearance of the
characteristic (C =O) band of 1 and 2 at 1685–1711 cm−1.
When compound 11 was reacted at ambient temperature
with sodium ethoxide in ethanol, the triazoloquinazoline
(14) could be obtained in 52% yield. According to literature
[20], reaction of compound 2 with hydrogen peroxide in
boiling glacial acetic acid, followed by treatment with hot
water, the corresponding triazolo[1,5-a]quinazolin-5-one
(4) was obtained in good yield. IR spectrum of compound
4 is characterized by a strong (C =O) absorption band at
1699 cm-1. Analogous to the reaction of 2 with hydrogen
peroxide, the corresponding compound 13 was obtained
from 12. The MS spectra of 4 and 13 showed molecular
ion peaks at m/z 263 and 282 (M•+, 100%), corresponding
to their molecular formulae. As well as the structures of 4
and 13 were characterized by NMR, MS, IR spectra, and
have been unambiguously proven by X-ray crystallography
(Figure 1).
Generally, uncorrected melting points of all compounds
were recorded and their chemical structures primarily con-
sistent with their IR and MS data (see experimental section)
and confirmed by 1H- and 13C NMR spectroscopy (splitting
pattern, δ- and J-values and comparison with literature of
structural related compounds). In the tricyclic nucleus, the
benzofused moiety was deduced from its own four one
proton 1H-signals as two dd (or br d) resonances with
Jortho (7.5-8.5 Hz) and Jmeta (1–2 Hz) assignable for
H-9 and H-6 and two td (or br t) resonances with
Figure 1 X-ray single crystal 3D-structures of compounds 4 and 13.
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exchangeable NH-proton was interpreted in 1H NMR
of 3 and 4 at δ > 13 ppm and were absent in all spectra of
N-alkyl or 5-chloro-triazoloquinazolines. 13C NMR
spectra proved the main tricyclic moiety through character-
istic nine resonances including the most downfield key
signal of C-2 assigned at ≈ 165 ppm in 2-phenoxy
derivatives (e.g. 3, 5–7) that was observed relatively
upfield at ≈ 160 in case of 2-methylsulfonyl function
(e.g. 4, 8–10) due to the stronger –R and –I (deshielding)
effect of O-phenoxy than -SO2. Another key
13C-signal
was C-5 that interpreted at δ ≈ 158–160 ppm in 5-ones
(3–10), ≈ 167 in 5-Cl derivatives (11,13) and ≈ 185 in case
of 5-thione (15). The 2-phenoxy function was easily
deduced from its intrinsic three resonances at ≈ 7.46
(td, J = 8.5, 2), 7.33 (br d, J = 8) and 7.26 (br t, J = 7.5)
for H-3′/5′, H-2′/6′ and H-4′ (5,10) and confirmed
through its four 13C resonances at δ ppm ≈ 154, 130,
124 and 119 interpretable for C-1′, 3′/5′, 4′, and 2′/6′,
respectively. Methylsulfonyl function was concluded from
its own 1H and 13C resonances of O2S-CH3 at ≈ 3.45 (s)
and 42 ppm, respectively. N-alkylation with p-nitrobenzyl
was unambiguously confirmed by its A2M2 spin coupling
system of the two ortho-doublets at about 8.2 and 7.7
(J = 8.5) for H-3″/5″ and H-2″/6″ together with the
downfield located CH2-singlet at ≈ 5.4 and its
13C-signal at
46 ppm by the deshielding effect of tertiary N-atom (5,10).
Whereas, alkylation with allyl moiety was proved by its
four characteristic 1H-resonances with intrinsic splitting
pattern at about 5.9 (m), 5.25 (dd, J = 17.5, 1.5), 5.20
(dd, J = 10.5, 1.5) and 4.72 (d, J = 5) assignable for olefinic
methine and methylene and CH2-saturated types (7,9).
The corresponding three 13C-resonances were interpreted
at δ ppm 131.2, 117.5 and 45.2 for C-2, C-3 and C-1 of
allyl group, respectively. In compound 18, 5-S-allyl
protons were interpreted with the same splitting pattern
but highly deshielded at 6.04, 5.42, 5.20 and 4.09 by
higher electronegativity of S-atom and their 13C-signalswere reported at 129.6 (C-2″), 115.1 (C-3″), and 32.1
(C-1″). Moreover, N-ethyl function was observed in
the form of a typical A2X3 spin coupling system as a
quartet (CH2) and triplet (CH3) at about 4.2 (q, J = 7)
and 1.3 (t, J = 7) and confirmed by their correspond-
ing 13C-resonances at δ ppm 38.5 and 12.4 (6,8). In
17 and 19 S-ethyl and S-phenyl functions showed the
same splitting pattern of N-ethyl and O-phenyl but with
slightly different δ-values in both 1H and 13C NMR spectra.
All other 1H- and 13C-resonances of all structures were
finally assigned on the basis of comparison with literature
data of structure related compounds and according to
application of substitution additive rules of 13C NMR.
Antihypertensive activity
In vivo antihypertensive activity study of the title
compounds 1–19 was performed by tail cuff method
using Muromachi Blood Pressure Monitor for rats and
mice (Model MK 2000). The obtained results, in Table 1,
revealed that the nature of substituent and substitution
pattern on the tricyclic systems 1–4 may have had a
considerable impact on the heart rate and blood pressure
in all synthesized derivatives (1–19).
Basically, the parent 1 was found to increase the heart
rate, however it has not demonstrated any effect on
blood pressure. Replacement of phenoxy group on
position 2 by a sulfanyl group in case of compound 2
has been abolished effect on the heart rate. On the
other hand, presence of sulfonyl group in 4 was found to
induce the bradycardia, however no effect on blood
pressure was noticed. Introduction of methyl group on
the lead compound 1 to afford 3 did offer advantageous
effect on reduction of blood pressure accomplished by
suppressing effect on heart rate in regard to 3. Alkylation
of lactam moiety in 1 furnished N-alkylated products 5–7,
that did demonstrate remarkable effect. For instance,
compound 5 was induced bradycardia, however great
increasing in the heart rate showed by 6, whereas
Table 1 Effects of compounds 1–19 on heart rate and
blood pressure
Compound % change in heart rate Decrease in the rats
arterial pressure (mm H)Decrease Increase
1 - 33.3 0
2 0 - 0
3 - 14.3 6.5
4 22.7 - 2.6
5 15 - 0
6 0 40 0
7 5.9 - 0
8 14.3 - 0
9 20 - 9.1
10 5.9 - 0
11 0 - 2.6
12 16.7 - 2.6 ↑
13 - 8.3 0
14 - 7.7 7.8
15 10 - 5.2
16 0 - 0
17 5.9 - 6.5
18 5.9 - 0
19 - 28.5 6.5
↑: Increase.
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on bradycardia was demonstrated by 7. Similarly, trans-
formation of 4 into 9 has emerged more bradycardia effect
accomplished by moderate decreasing on blood pressure.
However the product 8 showed induction on bradycardia
and 10 exhibited only bradycardia effect. Further
transformation of 1 into 11 does not seem to offer
any advantages effect on heart rate but a very slightly
decrease in blood pressure was observed. Whereas,
compound 12 showed more bradycardia and completely
abolished in tachycardia effects together with a slightly
increase on blood pressure. Moreover, decreasing on
tachycardia profile was exhibited by compound 13. The
replacement of the chlorine atom in 11 by ethoxide group
gave 14, which has shown decrease on blood pressure
and tachycardia effects. Thionation of 1 into 15 was
accomplished by abolishing the tachycardia profile
and induce on bradycardia term. The same behavior
on tachycardia effect was observed by compound 16
but no influence on blood pressure profile has been
recorded. Moreover, the transformation of 15 into 17
demonstrated almost the same behavior in the terms of the
effects on heart rate and blood pressure. Whereas, com-
pound 18 was exerted complete abolishing in tachycardia
and slight induction on bradycardia profiles. However,induction on tachycardia and decreasing on blood pressure
terms was demonstrated by compound 19.
Structure modifications on the lead compounds 1–4
have afforded derivatives with different effects on heart rate
and blood pressure profiles. Variation in the substituted
alkyl groups has demonstrated slightly remarkable activity
in regards to the parents, such as increasing on heart rate
emerged by 6, induction in bradycardia proved by 5 and
slightly decreasing in blood pressure occurred with 9. This
could be attributed to the characteristic features of their
alkyl groups. Introduction of lipophilic group on position 5
of the parent was appeared to offer slightly decrease
in blood pressure in case of compounds 11 and 12.
Nevertheless, the slight effect on blood pressure of 11 and
12 bearing at the 5-position a chlorine atom indicates that,
not only chloro lipophilic factor, but also the sterric effect
are important for decrease on blood pressure as shown by
14. Thionation targets 15 and 16 showed remarkable
attenuated on profiles activity, despite these compounds
possess enhanced lipophilicity comparable to that parent
compounds. However thioether products have almost
emerged the same behavior on blood pressure and heart
rate as in 17, and decreasing on blood pressure by 19.
The actual explanation for these changes regarding SAR




Melting points were determined on open glass capillaries
using a Mettler FP 62 apparatus and are uncorrected.
The IR (KBr, ѵ, cm-1) spectra were recorded on a Perkin
Elmer FT-IR Spectrum BX system. NMR spectra were
recorded on a Bruker AMX 500 spectrometer in
DMSO-d6 and reported as δ ppm values relative to TMS
at 500 and 125 MHz for 1H- and 13C NMR, respectively.
Mass spectra were measured on an Agilent 6410 TSQ
system connected to Agilent 1200 HPLC interface
(samples were infused in MeOH). Follow up of the
reactions and checking the purity of compounds was made
by TLC on DC-Mikrokarten polygram SIL G/UV254, from
the Macherey-Nagel Firm, Duren Thickness: 0.25 mm.
Column chromatography was conducted on silica gel (ICN
Silica 100–200, active 60 Å).
8-Methyl-2-phenoxy-4H-[1,2,4]triazolo[1,5-a]quinazolin-5-
one (3)
2-Hydrazino-5-methyl benzoic acid (10 mmol) was
added portion wise to a stirred solution of diphenyl-
N-cyanoimidocarabonate (10 mmol) in EtOH (20 mL)
at 0°C. Afterwards, triethylamine (30 mmol) was added
drop-wise over a period of 30 min. After the addition was
complete, the reaction mixture was left to stirr overnight
at room temperature. Acidification of the mixture was
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by refluxing for 1–3 h. After cooling, the mixture was
poured into ice/water, the resulting solid was filtered,
washed with water and dried. Recrystallization from
THF gave analytically pure colored as white solid,
yield: 77%, m.p. 218–220°C; IR (KBr): v/cm−1 1692,
(C = O), 3219 (NH); 1H NMR (DMSO-d6): δ = 13.04
(br s, 1H, NH), 7.98 (br s, 1H, H-6), 7.72 (br s, 2H,
H-7,9), 7.45 (td, J = 8.5, 2 Hz, 2H, H-3′/5′), 7.32 (br d,
J = 8 Hz, 2H, H-2′/6′), 7.25 (br t, J = 7.5 Hz, 1H, H-4′),
2.45 (s, 3H, Ar-CH3);
13C NMR (DMSO-d6): δ = 165.7
(C-2), 159.4 (C-5), 154.2 (C-1′), 147.1 (C-9a), 136.2
(C-8), 135.3 (C-3a), 133.6 (C-5a), 129.7 (C-3′/5′),
127.8 (C-6), 124.9 (C-4′), 119.4 (C-2′/6′), 116.6 (C-7),
114.1 (C-9), 20.5 (Ar-CH3); MS (ESI) negative mode:
m/z 291.1 (M- - 1) for MW= 292.
2-Methylsulfonyl-4H-[1,2,4]triazolo[1,5-a]quinazolin-5-one (4)
An amount of 2-methylsulfanyl-4H-[1,2,4]triazolo[1,5-a]
quinazolin-5-one (1 mmol) was dissolved in bioling glacial
acetic acid (10 mL), afterward H2O2 (10 mL), was added
drop-wise over a period of 5 min. while heating. After the
addition was complete, the mixture was poured into hot
water and left at room temperature, the resulting solid was
filtered, washed with water and dried. Recrystallization
from toluene gave analytically pure colored as white solid,
yield: 50%, m.p. 261–263°C; IR (KBr): v/cm−1 1690 (C =O)
3240 (NH); 1H NMR (DMSO-d6): δ = 13.39 (br s, 1H, NH),
8.22 (br d, J = 8 Hz, 1H, H-9), 8.04 (br d, J = 8 Hz, 1H, H-6),
7.97 (br t, J = 7.5 Hz, 1H, H-8), 7.65 (br t, J = 7.5 Hz, 1H,
H-7), 3.35 (s, 3H, O2S-CH3);
13C NMR (DMSO-d6):
δ = 160.9 (C-2), 160.2 (C-5), 149.9 (C-9a), 135.4 (C-8),
135.3 (C-3a), 128.4 (C-6), 127.2 (C-5a), 118.0 (C-7), 114.8
(C-9), 42.0 (O2S-CH3); MS (ESI) (negative mode): m/z
263.1 (M- - 1), (positive mode): m/z 265.0 (M+ + H), 287.1
(M+ + Na) for MW= 264.
General procedure for synthesis of 2-phenoxy(methylsulfonyl)-
4-alkyl(aralkyl)-[1,2,4]-triazolo[1,5-a]quinazolin-5-ones (5–10)
To a solution of 1 or 4 (I mmol) in DMF (5 mL) was
added potassium carbonate (1.2 mmol) portion wise over
a period of 10 min at room temperature. After stirring for
20 min, the appropriate alkyl halide (1.5 mmol) was added
drop wise, and the reaction mixture was stirred for 18 h
at room temperature. The mixture was poured into
ice/water, the precipitate was filtered off, washed with
water and dried. Analytically pure products 5–10 were
obtained after recrystallization from THF.
2-Phenoxy-4-(p-nitrobenzyl)-[1,2,4]triazolo[1,5-a]quinazolin-
5-one (5)
White solid, yield: 78%, m.p. 190–192°C; IR (KBr): v/cm−1
1677 (C =O); 1H NMR (DMSO-d6): δ = 8.25 (dd, J = 8,
1 Hz, 1H, H-9), 8.19 (d, J = 8.5 Hz, 2H, H-3″/5″), 7.95(td, J = 8.5, 1.5 Hz, 1H, H-8), 7.87 (br d, J = 8 Hz, 1H,
H-6), 7.71 (d, J = 8.5 Hz, 2H, H-2″/6″), 7.59 (td, J = 8,
1 Hz, 1H, H-7), 7.46 (td, J = 8.5, 2 Hz, 2H, H-3′/5′),
7.33 (br d, J = 8 Hz, 2H, H-2′/6′), 7.26 (br t, J = 7.5 Hz,
1H, H-4′), 5.43 (s, 2H, –CH2-Ar);
13C NMR (DMSO-d6):
δ = 165.2 (C-2), 158.7 (C-5), 154.1 (C-1′), 148.4 (C-9a),
146.9 (C-4″), 143.4 (C-1″), 135.8 (C-8), 135.3 (C-3a),
129.8 (C-3′/5′), 128.8 (C-2″/6″), 128.6 (C-6), 126.0
(C-5a), 124.9 (C-4′), 121.5 (C-3″/5″), 119.0 (C-2′/6′),
116.2 (C-7), 114.2 (C-9), 46.1 (−CH2-Ar); MS (EI): m/z (%)
413 (M•+, 92) for MW= 413.
4-Ethyl-2-phenoxy-[1,2,4]triazolo[1,5-a]quinazolin-5-one (6)
White solid, yield: 73%, m.p. 165–167°C; IR (KBr): v/cm−1
1675 (C =O ); 1H NMR (DMSO-d6): δ = 8.23 (dd, J = 8,
1 Hz, 1H, H-9), 7.92 (td, J = 8.5, 1.5 Hz, 1H, H-8), 7.83
(br d, J = 8 Hz, 1H, H-6), 7.56 (td, J = 8.5, 1 Hz, 1H,
H-7), 7.46 (td, J = 8.5, 1 Hz, 2H, H-3′/5′), 7.35 (dd, J = 8.5,
1 Hz, 2H, H-2′/6′), 7.27 (br t, J = 7.5 Hz, 1H, H-4′), 4.15
(q, J = 7 Hz, 2H, –CH2-CH3), 1.29 (t, J = 7 Hz, 3H, –CH2-
CH3);
13C NMR (DMSO-d6): δ = 165.4 (C-2), 158.3 (C-5),
154.2 (C-1′), 148.2 (C-9a), 135.4 (C-8), 135.0 (C-3a), 129.8
(C-3′/5′), 128.4 (C-6), 125.8 (C-5a), 124.9 (C-4′), 119.1
(C-2′/6′), 116.3 (C-7), 114.1 (C-9), 38.5 (−CH2-CH3), 12.4




White solid, yield: 85%, m.p. 133–135°C; IR (KBr): v/cm−1
1684 (C =O); 1H NMR (DMSO-d6): δ = 8.23 (br d, J= 8 Hz,
1H, H-9), 7.92 (td, J = 8.5, 1.5 Hz, 1H, H-8), 7.83 (br d,
J = 8 Hz, 1H, H-6), 7.57 (td, J = 8.5, 1 Hz, 1H, H-7),
7.47 (td, J = 8.5, 1 Hz, 2H, H-3′/5′), 7.35 (dd, J = 8.5,
1 Hz, 2H, H-2′/6′), 7.27 (br t, J = 7.5 Hz, 1H, H-4′),
5.97 (m, 1H, H-2″), 5.24 (dd, J = 17.5, 1.5 Hz, 1H, H-3a″),
5.19 (dd, J = 10.5, 1.5 Hz, 1H, H-3b″), 4.72 (d, J = 5 Hz,
2H, H-1″); 13C NMR (DMSO-d6): δ = 165.4 (C-2), 158.2
(C-5), 154.2 (C-1′), 148.2 (C-9a), 135.5 (C-8), 135.1
(C-3a), 131.2 (C-2″), 129.8 (C-3′/5′), 128.5 (C-6),
125.9 (C-5a), 124.9 (C-4′), 119.1 (C-2′/6′), 117.5 (C-3″),
116.1 (C-7), 114.1 (C-9), 45.2 (C-1″); MS (EI): m/z (%)
318 (M•+, 98) for MW= 318.
4-Ethyl-2-methylsulfonyl-[1,2,4]triazolo[1,5-a]quinazolin-5-
one (8)
White solid, yield: 71%, m.p. 187–189°C; IR (KBr): v/cm−1
1675 (C =O); 1H NMR (DMSO-d6): δ = 8.27 (br d, J = 8 Hz,
1H, H-9), 8.07 (br d, J = 8 Hz, 1H, H-6), 8.00 (br t,
J = 7.5 Hz, 1H, H-8), 7.69 (br t, J = 7.5 Hz, 1H, H-7), 4.22
(q, J = 6.5 Hz, 2H, –CH2–CH3), 3.49 (s, 3H, O2S -CH3),
1.34 (t, J = 6.5 Hz, 3H, –CH2–CH3);
13C NMR (DMSO-d6):
δ = 160.8 (C-2), 158.3 (C-5), 149.8 (C-9a), 135.5 (C-8),
134.5 (C-3a), 128.6 (C-6), 127.6 (C-5a), 117.4 (C-7), 114.8
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MS (EI):m/z (%) 292 (M•+, 89 ) for MW=292.
4-Allyl-2-methylsulfonyl-[1,2,4]triazolo[1,5-a]quinazolin-5-
one (9)
White solid, yield: 87%, m.p. 152–154°C; IR (KBr): v/cm−1
1684 (C=O); 1H NMR (DMSO-d6): δ= 8.27 (br d, J= 8 Hz,
1H, H-9), 8.10 (br d, J= 8 Hz, 1H, H-6), 8.03 (br t, J= 7.5 Hz,
1H, H-8), 7.70 (br t, J= 7.5 Hz, 1H, H-7), 6.00 (m, 1H, H-2′),
5.31 (br d, J= 17.5 Hz, 1H, H-3a′), 5.21 (br d, J= 10.5 Hz,
1H, H-3b′), 4.80 (d, J = 5 Hz, 2H, H-1′), 3.48 (s, 3H,
O2S –CH3);
13C NMR (DMSO-d6): δ = 160.7 (C-2),
158.3 (C-5), 149.9 (C-9a), 135.7 (C-8), 134.8 (C-3a),
131.0 (C-2′), 128.7 (C-6), 127.7 (C-5a), 117.6 (C-3′),
117.2 (C-7), 114.9 (C-9), 45.5 (C-1′), 42.0 (O2S -CH3);
MS (EI): m/z (%) 304 (M•+, 100) for MW= 304.
4-(p-Nitrobenzyl)-2-methylsulfonyl-[1,2,4]triazolo[1,5-a]
quinazolin-5-one (10)
White solid, yield: 72%, m.p. 199–201°C; IR (KBr):
v/cm−1 1678 (C =O); 1H NMR (DMSO-d6): δ = 8.29 (br d,
J = 8 Hz, 1H, H-9), 8.19 (d, J = 8.5 Hz, 2H, H-3′/5′), 8.14
(br d, J = 8 Hz, 1H, H-6), 8.05 (br t, J = 7.5 Hz, 1H, H-8),
7.75 (d, J = 8.5 Hz, 2H, H-2″/6″), 7.72 (br t, J = 7.5 Hz, 1H,
H-7), 5.51 (s, 2H, –CH2-Ar), 3.47 (s, 3H, O2S –CH3);
13C NMR (DMSO-d6): δ = 160.6 (C-2), 158.8 (C-5), 150.2
(C-9a), 146.9 (C-4′), 143.2 (C-1′), 135.9 (C-8), 135.0
(C-3a), 128.7 (C-2′/6′), 128.7 (C-6), 127.7 (C-5a),
123.5 (C-3′/5′), 117.3 (C-7), 114.9 (C-9), 46.5 (−CH2-
Ar), 42.0 (O2S –CH3); MS (EI): m/z (%) 399 (M
•+,90 )
for MW = 399.
5-Chloro-2-phenoxy-[1,2,4]triazolo[1,5-a]quinazoline (11)
Compound 1 (1 mmol) was refluxed with Phosphorous
oxychloride (1 mL) in benzene (7 mL) for 2.5 h. The solvent
was evaporated and the residue was treated with saturated
solution of potassium carbonate. The solid was filtered,
washed thoroughly with water, dried and recrystallized from
THF to give pure compound as white solid, yield: 82%, m.p.
167–169°C; 1H NMR (DMSO-d6): δ = 8.07 (br d, J= 8 Hz,
1H, H-9), 7.64 (m, 2H, H-6/8), 7.40 (td, J = 8.5, 1 Hz, 2H,
H-3′/5′), 7.30 (td, J = 8.5, 1 Hz, 1H, H-7), 7.25 (dd, J= 8.5,
1 Hz, 2H, H-2′/6′), 7.18 (br t, J = 8 Hz, 1H, H-4′);
13C NMR (DMSO-d6): δ = 167.6 (C-2), 166.3 (C-5),
157.0 (C-9a), 155.0 (C-1′), 136.3 (C-3a), 131.7 (C-8),
129.4 (C-3′/5′), 128.0 (C-7), 123.8 (C-4′), 123.0 (C-6),
119.0 (C-2′/6′), 118.6 (C-5a), 112.9 (C-9). MS (EI): m/z
(%) 296 (M•+, 100) for MW= 296.
5-Chloro-2-methylsulfonyl-[1,2,4]triazolo[1,5-a]quinazoline (13)
1 mmol of 2-methylsulfanyl-5-chloro-[1,2,4]triazolo[1,5-
a]quinazoline was dissolved in bioling glacial acetic acid
(10 mL), afterward H2O2 (10 mL) was added drop-wise
over a period of 5 min. while heating. After the additionwas complete, the mixture was poured into hot water and
lef at room temperature, the resulting solid was filtered,
washed with water and dried. Recrystallization from
Toluene gave analytically pure colored as white solid, yield:
62%, m.p. 196–198°C; 1H NMR (DMSO-d6): δ = 8.21 (br d,
J = 8 Hz, 1H, H-9), 7.99 (m, 2H, H-6/8), 7.66 (br t, J = 7 Hz,
1H, H-7), 3.54 (s, 3H, O2S-CH3);
13C NMR (DMSO-d6):
δ = 162.9 (C-5), 160.9 (C-2), 158.6 (C-9a), 137.3 (C-3a),
135.5 (C-8), 128.8 (C-7), 127.4 (C-6), 118.5 (C-5a), 114.7




A freshly prepared sodium ethoxide solution from sodium
(150 mg) and absolut ethanol (35 mL) was reacted with
compound 11 (1 mmol) by stirring at room temperature
for 30 min. Afterwards the solid was collected by filtration,
air dried, and recrystallized from THF to give product as
white solid, yield: 56%, m.p. 197–199°C; IR (KBr): v/cm−1
1602 (C=N); 1H NMR (DMSO-d6): δ= 8.15 (br d, J= 8 Hz,
1H, H-9), 7.71 (br t, J= 7.5 Hz, 1H, H-8), 7.65 (br d, J= 8 Hz,
1H, H-6), 7.49 (dt, J= 8.5, 1 Hz, 2H, H-3′/5′), 7.43 (br t,
J = 7.5 Hz, 1H, H-7), 7.36 (dd, J = 8.5, 1 Hz, 2H, H-2′/6′),
7.04 (br t, J = 8 Hz, 1H, H-4′), 3.72 (q, J = 7 Hz, 2H, CH2),
1.57 (t, J = 7 Hz, 3H, CH3);
13C NMR (DMSO-d6): δ = 167.3
(C-2), 155.5, (C-5), 154.2 (C-9a), 150.7 (C-1′), 135.6 (C-3a),
133.5 (C-8), 129.8 (C-3′/5′), 127.9 (C-7), 123.8 (C-4′),
123.0 (C-6), 119.6 (C-2′/6′), 118.9 (C-5a), 112.9 (C-9), 24.1
(−CH2CH3), 13.9 (−CH2CH3); MS (EI): m/z (%) 306
(M•+, 73) for MW= 306.
2-Phenoxy-4H-[1,2,4]triazolo[1,5-a]quinazolin-5-thione (15)
Compounds 1 (1 mmol) was refluxed with phosphorous
pentasulfide (1 mmol) in absolute pyridine (5 mL) for 3 h.
Afterwards the reaction mixture was cooled and poured
into ice/water, the yellow precipitate was separated by filtra-
tion and washed thoroughly with water. Recrystallization
from aqueous dimethylformamide furnished analytically
pure as yellow solid, yield: 92%, m.p. 209–211°C; IR (KBr):
v/cm−1 1197 (C = S); 1H NMR (DMSO-d6): δ = 8.64
(dd, J = 8, 1 Hz, 1H, H-9), 7.95 (br dt, J = 7.5, 1 Hz,
1H, H-8), 7.89 (br d, J = 7.5 Hz, 1H, H-6), 7.56 (td, J = 8,
1 Hz, 1H, H-7), 7.47 (td, J = 8.5, 1 Hz, 2H, H-3′/5′), 7.35
(dd, J = 8.5, 1 Hz, 2H, H-2′/6′), 7.27 (br t, J = 7.5 Hz, 1H,
H-4′); 13C NMR (DMSO-d6): δ = 185.3 (C-5), 165.0 (C-2),
154.2 (C-1′), 149.3 (C-9a), 135.9 (C-8),132.4 (C-3a), 131.8
(C-5a), 129.8 (C-3′/5′), 126.3 (C-6), 125.0 (C-4′), 123.9
(C-7), 119.4 (C-2′/6′), 114.5 (C-9); MS (EI): m/z (%) 294
(M+, 90) for MW= 294.
General procedure for synthesis of 5-Alkyl(phenyl)sulfanyl-
2-phenxy-[1,2,4]triazolo[1,5-a]-quinazolines (17–19)
Compound 15 (1 mmol) was dissolved in 2 M sodium
hydroxide solution (10 mL), alkyl halide (1.5 mmol) was
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left to stir for I h at room temperature, and the
obtained solid was separated by filtration, washed
thoroughly with water and dried. Recrystallization of
the crude products from THF afforded 17–19 as colored
pure solid.5-Ethylsulfanyl-2-phenoxy-[1,2,4]triazolo[1,5-a]quinazoline (17)
White solid, yield: 68%, m.p. 185–187°C; 1H NMR
(DMSO-d6): δ = 8.26 (br d, J = 8 Hz, 1H, H-9), 7.75 (br t,
J = 7.5 Hz, 1H, H-8), 7.77 (br d, J = 8 Hz, 1H, H-6), 7.63
(dt, J = 8.5, 1 Hz, 2H, H-3′/5′), 7.51 (br t, J = 7.5 Hz, 1H,
H-7), 7.41 (dd, J = 8.5, 1 Hz, 2H, H-2′/6′), 7.11 (br t,
J = 8 Hz, 1H, H-4′), 4.39 (q, J = 7.2 Hz, 2H, CH2),
1.41 (t, J = 7.2 Hz, 3H, CH3);
13C NMR (DMSO-d6):
δ = 167.9 (C-2), 156.7, (C-5), 154.0 (C-9a), 150.9 (C-1′),
136.1 (C-3a),134.8 (C-8), 130.1 (C-3′/5′), 128.3 (C-7),
125.2 (C-4′), 123.9 (C-6), 120.3 (C-2′/6′), 119.1 (C-5a),
112.1 (C-9), 62.1 (−CH2CH3), 13.9 (−CH2CH3); MS (EI):
m/z (%) 322 (M•+, 72) for MW= 322.5-Allylsulfanyl-2-phenoxy-[1,2,4]triazolo[1,5-a]quinazoline (18)
Yellow solid, yield: 75%, m.p. 109–111°C; 1H NMR
(DMSO-d6): δ = 8.08 (br d, J = 8 Hz, 1H, H-9), 7.72
(td, J = 8.5, 1.5 Hz, 1H, H-8), 7.66 (br d, J = 8 Hz, 1H,
H-6), 7.37 (td, J = 8.5, 1 Hz, 2H, H-3′/5′), 7.33 (td, J = 8.5,
1 Hz, 1H, H-7), 7.25 (dd, J = 8.5, 1 Hz, 2H, H-2′/6′), 7.17
(br t, J = 7.5 Hz, 1H, H-4′), 6.04 (m, 1H, H-2″), 5.42
(dd, J = 17.5, 1.5 Hz, 1H, H-3a″), 5.20 (dd, J = 10.5,
1.5 Hz, 1H, H-3b″), 4.09 (d, J = 6.5 Hz, 2H, H-1″); 13C
NMR (DMSO-d6): δ = 167.4 (C-2), 166.6 (C-5), 154.9
(C-1′), 154.2 (C-5a), 151.0 (C-9a), 136.2 (C-3a), 135.7
(C-8), 129.6 (C-2″), 129.5 (C-3′/5′), 127.9 (C-6),
125.0 (C-7), 123.9 (C-4′), 119.0 (C-2′/6′), 115.1 (C-3″),
112.9 (C-9), 32.1 (C-1″); MS (EI): m/z (%) 334 (M•+, 89) for
MW=334.2-Phenoxy-5-phenylsulfanyl-[1,2,4]triazolo[1,5-a]quinazoline (19)
Yellow solid, yield: 54%, m.p. 172–174°C; 1H NMR
(DMSO-d6): δ = 8.81 (br dd, J = 8.5, 1 Hz, 1H, H-9), 7.78
(br d, J = 8 Hz, 1H, H-6), 7.71 (td, J = 8.5, 1.5 Hz, 1H, H-8),
7.66 (td, J = 8.5, 1 Hz, 1H, H-7), 7.43 (td, J = 8.5, 1 Hz, 2H,
H-3′/5′), 7.38(td, J = 8.5, 1 Hz, 2H, H-3″/5″), 7.31
(dd, J = 8.5, 1 Hz, 2H, H-2′/6′), 7.27 (dd, J = 8.5,
1 Hz, 2H, H-2″/6″), 7.21 (br t, J = 8 Hz, 1H, H-4′),
7.17 (br t, J = 7.5 Hz, 1H, H-4″); 13C NMR (DMSO-d6):
δ= 166.8 (C-2), 155.0 (C-5), 154.8 (C-1′), 152.4 (C-3a), 132.9
(C-9a), 132.3 (C-8), 132.1 (C-3″/5″), 129.5 (C-3′/5′, 1″),
129.4 (C-4″), 127.9 (C-5a), 124.2 (C-4′,2″/6″), 123.8 (C-6),
(C-3′/5′), 119.1 (C-2′/6′), 119.0 (C-7), 113.5 (C-9); MS
(EI): m/z (%) 370 (M+, 74 ) for MW= 370.Antihypertensive activity
In vivo antihypertensive activity study of the title
compounds was performed by tail cuff method using
Blood Pressure Monitor for rats and mice (Model
MK 2000- Muromachi kikkai Co. ltd. Japan). The samples
of the investigated compounds were administered orally at
a dose of 5 mg/kg as suspension in 1% sodium carboxy
methyl cellulose. Measurements (blood pressure and heart
rate) were recorded before and after the treatment of
tested compounds at the intervals of 1 h for 5 h.
Conclusions
Since compounds 4, 8, 9, 12, and 15 have abolished
completely the tachycardia of the parent compounds,
they may be studied as potential adrenoblockers.
Compounds 9 and 14 may be modified to enhance their
hypotensive activity. Furthermore, compound 6 seem to
be a cardiac stimulant and it will be studied further for
this concern. Finally, the structure–activity relationship
(SAR) study of the compounds gave us some useful
insights about the characteristic requirements, which
may be taken into consideration in the design of new
antihypertensive agents.
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